Could a chemo drug tame a rare immune disorder?
NCT ID NCT07555405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the drug decitabine in 6 boys with XMEN disease, a rare genetic condition that weakens the immune system and damages the liver. The goal is to see if decitabine can improve liver function and immune cell activity. It is a very early, small trial focused on safety and signs of benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Decitabine (a chemotherapy drug given by IV)
What this could lead to
If it works, this could point toward a treatment for XMEN disease, a rare immune disorder that makes patients prone to severe infections and liver problems.
What could go wrong
This is a very small, early trial with only 6 participants, so results may not apply to everyone. Decitabine is a chemotherapy drug and can cause serious side effects like low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAGT1 DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, 201102, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••